Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05235685

Neuromuscular Fatigue During Exercise in COPD-HF Overlap

Led by University Hospital, Grenoble · Updated on 2024-06-24

40

Participants Needed

1

Research Sites

144 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Rationale. Chronic obstructive pulmonary disease (COPD) and heart failure (HF) coexist in approximately one third of patients presenting with one of these conditions. From a clinical standpoint, impaired tissue oxygen (O2) delivery stands as a common pathological mechanism of these cardiorespiratory diseases. Recent evidence suggest that muscle and cerebral blood flow and oxygenation are further impaired during exercise in patients with COPD-HF overlap compared to isolated diseases. However, it remains unknown whether impaired O2 delivery is associated with exaggerated manifestations of peripheral and central fatigue in COPD-HF overlap. In addition, improving cardiopulmonary interactions through non invasive positive pressure ventilation or through the addition of a hyperoxic gas mixture during exercise have been associated with enhanced cerebral and muscle O2 delivery and oxygenation in patients with COPD or HF. It is, therefore, conceivable that improved O2 delivery to these structures have beneficial influence on exercise capacity in patients with COPD-HF overlap due to less peripheral and central fatigue. Aims. To investigate the influence of impaired O2 delivery during exercise, and its alleviation with different interventions (non invasive positive pressure ventilation or hyperoxia), on neuromuscular fatigue in patients with COPD-HF.

CONDITIONS

Official Title

Neuromuscular Fatigue During Exercise in COPD-HF Overlap

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosis of COPD with mild-to-severe airflow obstruction (FEV1/FVC ratio <0.70; post-bronchodilator FEV1 > 30% predicted)
  • Heart failure with reduced left ventricular ejection fraction (<50%) for COPD-HF patients
  • New York Heart Association Functional Classification I to III for COPD-HF patients
  • Clinical stability for both COPD and/or heart failure with no exacerbations requiring medication changes in the past 3 months
  • Patient benefits from health care coverage
  • Patient able to provide written informed consent
Not Eligible

You will not qualify if you...

  • Unable to perform cycle ergometry exercise test
  • Having medical devices incompatible with magnetic stimulation
  • Contraindication to exercise testing
  • Refusal to sign written informed consent
  • Not benefiting from health care coverage
  • Exceeding annual authorized compensation limits from clinical trial participation
  • Deprived of freedom by judicial or administrative decision
  • Under legal protection measures (safeguard of justice, guardianship, curatorship) preventing clinical trial inclusion
  • Pregnant or nursing women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHU Grenoble Alpes - Hopital Sud (Laboratoire HP2)

Échirolles, Auvergne-Rhône-Alpes, France, 38130

Actively Recruiting

Loading map...

Research Team

S

Stéphane Doutreleau, MD, PhD

CONTACT

M

Mathieu Marillier, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here